title: Comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
authors.forename: Ajay
authors.initials: A
authors.lastname: Chaudhuri
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
authors.forename: Nitesh
authors.initials: N
authors.lastname: Kuhadiya
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
authors.forename: Husam
authors.initials: H
authors.lastname: Ghanim
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY pdandona@kaleidahealth.org.
authors.forename: Paresh
authors.initials: P
authors.lastname: Dandona
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D010455:Peptides / Q000008:administration & dosage*; D014688:Venoms / Q000008:administration & dosage*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms